Does a company 's share price skyrocket
0
Shares of drug company BeiGene soar in US <EOP> .
########
1
2018_01_05 16:03 <EOP> .
########
2
China Daily USA <EOP> .
########
3
The share price of Nasdaq_listed Chinese biopharmaceutical company BeiGene more than tripled in 2017 even though its products have not yet been put on the market , indicating investors ' strong interest in the company 's offerings .
price	2	CT+	CT+
not	19	neg_cue
yet	20	neg_cue
########
4
<EOP> .
########
5
Even though it 's rare for a company 's share price to skyrocket when its products are yet to be offered , a report from the Motley Fool , a US investment analytics website , indicates there is still more potential for the stock to grow , supported by BeiGene 's fundamentals .
price	10	PS-	CT+
rare	4	ps_cue
yet	17	neg_cue
potential	40	ps_cue
########
6
<EOP> .
########
7
BeiGene is a commercial_stage , research_based biopharmaceutical company focused on molecularly targeted and immune_oncology cancer therapeutics .
########
8
Its share price rose from some $ 30 to more than $ 96 in 2017 , with capitalization of about $ 4.4 billion .
price	2	CT+	CT+
########
9
<EOP> .
########
10
The capital market `` is showing strong interest in innovative biopharmaceutical projects in China and abroad .
########
11
For successful investment , long_term strategies and investors with great vision and patience are key '' , said a research report at Healthcare Executives , a professional healthcare journal .
########
12
<EOP> .
########
13
Besides BeiGene , several other Chinese biotech companies are also favored in global capital markets , such as cancer therapeutics biotech BeyondSpring and Zai Lab , a Shanghai_based biopharmaceutical company that focuses on transformative medicines for cancer , autoimmune and infectious diseases .
########
14
Both BeyondSpring and Zai Lab went public on the Nasdaq in 2017 .
########
15
<EOP> .
########
16
John Oyler , founder and chief executive officer and chairman of BeiGene , said the company hopes its original products will be successfully offered in China to enable patients to benefit from the drugs in affordable manner .
hopes	16	ps_cue
will	20	ps_cue
########
17
<EOP> .
########
18
BeiGene has established a manufacturing base in Suzhou , Jiangsu province that can produce up to 100 million capsules annually , meeting the demands of some 20,000 to 50,000 patients .
can	12	ps_cue
########
19
It also has a macromolecular biotics manufacturing base under construction in Guangzhou .
########
20
The two plants are preparing to produce the company 's new drugs , which are still in clinical research stage and yet to be commercialized .
yet	21	neg_cue
########
21
<EOP> .
########
22
According to data from IMS , a pharmaceutical and healthcare consultancy services provider , China is the world 's second largest consumer of medicine , after the US .
########
23
<EOP> .
########
24
Chinese healthcare and medicine regulators have also made efforts to reform the drug review and approval system , which shortens time for a new drug to be widely used and encourages innovations and enables investors to achieve returns in a shorter period of time , said Song Ruilin , executive president of China Pharmaceutical Innovation and Research Development Association , at a recent conference .
########
25
<EOP> .
########
26
wuyiyao@chinadaily.com.cn <EOP> .
########
